4 years ago

Kuano.ai Secures £1 Million Seed Funding to Advance AI-Driven Drug Discovery

  • London-based AI biotech company Kuano.ai has raised £1 million in seed funding to transform drug discovery through a unique approach combining quantum physics, AI, and medicinal chemistry

  • The funding, provided by ACF Investors, o2h Ventures, and Cambridge-based angel investors, will be used to expand the technology team, further develop the company's platform and asset development, and create a data bank for collaborations

  • Kuano.ai's focus on enzyme inhibition addresses a significant market demand for improved drug potency, selectivity, and reduced resistance.

      • ProblemBiotechnology

      "Developing novel therapeutics for treating degenerative neurological disorders, such as Alzheimer's disease"

      Solution

      "Using AI, quantum physics, and medicinal chemistry to discover enzyme inhibitors and create more effective medicines"

      Covered on